Amneal Pharmaceuticals, Inc. (AMRX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$18.26

From 52W high−2.04%

Volume6.48M

Market cap$5.98B

P/E (TTM)37.6x

P/S (TTM)1.9x

Div yield—

Key dataSep 18, 2026

Open

$18.26

From 52W high

−2.04%

Volume

6.48M

Market cap

$5.98B

ValuationView details →

P/E (Fwd)

18.8x

EV/EBITDA

13.4x

P/E (TTM)

37.6x

RSI (14)

58.4

MomentumView details →

1D Return

+2.35%

YTD Return

+46.03%

SummaryUpdated Jun 1, 2026

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is a specialty and generic pharmaceutical company founded in 2002 and headquartered in Bridgewater, New Jersey. The company went public in May 2018 following its transformation from Atlas Holdings, Inc. Amneal has evolved from a traditional generic drug manufacturer into a diversified pharmaceutical company with operations spanning generic medicines, specialty branded products, and healthcare distribution services. The company operates manufacturing facilities in the United States, India, and Ireland, serving customers globally through a comprehensive portfolio of pharmaceutical products and services.

Ask drillr about Amneal Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

18.8x

P/E (TTM)

37.6x

EV/EBITDA

13.4x

EV/Sales

2.8x

P/S (TTM)

1.9x

P/B (TTM)

180.9x

ProfitabilityView details →

Gross Margin

39.32%

Net Margin

5.05%

EBITDA Margin

20.92%

ROE (TTM)

476.51%

ROA (TTM)

4.17%

Asset Turnover

0.85x

GrowthView details →

Revenue YoY

+9.28%

EPS YoY

+4825.74%

FCF YoY

−68.34%

Revenue CAGR 3Y

+10.92%

EPS CAGR 3Y

+160.53%

EBITDA YoY

+11.70%

MomentumView details →

1D Return

+2.35%

YTD Return

+46.03%

1Y Return

+87.56%

RSI (14)

58.4

vs 50D SMA

+3.24%

vs 200D SMA

+25.91%

Capital & dividendView details →

Debt/Equity

84.54x

Current Ratio

2.20x

Quick Ratio

1.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.30

EPS Surprise

34.83%

Beats (12Q)

11/12

Next Q EPS Est

$0.23

Avg Surprise (4Q)

41.34%

Rev Surprise

3.64%

Financials snapshotView financials →

Revenue (TTM)

3.12B

Net Income (TTM)

157.36M

Op. CF (TTM)

200.78M

Next earningsOct 29, 2026 →

Latest newsMore news →

The FDA approved Amneal Pharmaceuticals' Lanreotide Injection, a long-acting oncology treatment, and Amneal immediately launched the product commercially.2d ago

Amneal Pharmaceuticals (AMRX) shares surged 8.6% in the prior session on above-average trading volume.3d ago

Similar companies

China Shineway Pharmaceutical Group Limited02877.HK China Traditional Chinese Medicine Holdings Co. Limited00570.HK 辰欣药业603367.SH 华纳药厂688799.SH 昆药集团600422.SH 津药药业600488.SH Find similar companies →

Latest newsMore news →

The FDA approved Amneal Pharmaceuticals' Lanreotide Injection, a long-acting oncology treatment, and Amneal immediately launched the product commercially.2d ago Amneal Pharmaceuticals (AMRX) shares surged 8.6% in the prior session on above-average trading volume.3d ago